SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.
Under the $362 million deal with Vir Biotechnology announced Friday, Samsung Biologics will manufacture antibody treatments that have received preliminary approval from the U.S. Food and Drug Administration. Clinical trials are set to begin within the year.
